XML 62 R49.htm IDEA: XBRL DOCUMENT v3.24.1
Operating Segments (Tables)
 12 Months Ended
Dec. 31, 2023
Operating Segments [Abstract]  
Schedule of Operating Segments The Group’s CODM is the CEO of the Company.
   Year ended December 31, 2023 
   Drug Development   Online Sales   Total 
Revenues            
External  $
-
   $2,879   $2,879 
Total   
-
    2,879    2,879 
                
Segment loss (gain)   5,359    414    5,773 
Company’s share of losses of company accounted for at equity, net             210 
Loss on impairment of intangible asset             1,042 
Finance expense (income), net             (1,164)
Tax expense             22 
                
 Loss             5,883 
   Year ended December 31, 2022 
   Drug
Development		   Online
Sales		   Total 
Revenues            
External  $
-
   $1,347   $1,347 
Total   
-
    1,347    1,347 
                
Segment loss   8,405    (118)   8,287 
Company’s share of losses of company accounted for at equity, net             109 
Finance expense (income), net             (5,818)
Tax expense             14 
                
 Loss             2,592 

 

   Year ended December 31, 2021 
   Drug
Development		   Online
Sales		   Total 
Revenues            
External  $
-
   $
       -
   $
-
 
Total   
-
    
-
    
-
 
                
Segment loss   5,768    
-
    5,768 
Finance expense (income), net             21 
                
Loss             5,789 
   As of December 31, 2023 
   Drug
Development		   Online
Sales		   Total 
             
Segment Assets  $7,069   $4,113   $11,182 
Segment Liabilities  $1,441   $154   $1,595 
   As of December 31, 2022 
   Drug
Development		   Online
Sales		   Total 
             
Segment Assets  $9,664   $941   $10,605 
Segment Liabilities  $4,021   $135   $4,156